IIM
NBIX icon

Ipswich Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Ipswich Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-150
Closed -$11K – 307
2018
Q4 		$11K Buy
+150
New +$14.4K ﹤0.01% 367

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ipswich Investment Management's NBIX Position: Q1 2019 in Review

Ipswich Investment Management sold out of Neurocrine Biosciences (NBIX) in Q1 2019, closing a stake of 150 shares — an estimated $11K sold.

Ipswich Investment Management first reported a position in NBIX in Q4 2018 and held it in 1 quarter. The position peaked at $11K in Q4 2018. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • Ipswich Investment Management reported no remaining Neurocrine Biosciences position as of Q1 2019 after selling out during the quarter.
  • Ipswich Investment Management sold 150 Neurocrine Biosciences shares in Q1 2019, an estimated $11K.
  • Ipswich Investment Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 1 quarter.
  • Ipswich Investment Management's Neurocrine Biosciences position peaked at $11K in Q4 2018.
  • 325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on Ipswich Investment Management's 13F filing for Q1 2019, filed 12 Apr 2019.